Christopher G. Bunick, MD, PhD

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.

The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.

Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.

A panel of experts review the nature of plaque psoriasis and the mechanism of action of several classes of targeted therapy.